|1.||Wang, Guoqiang: 3 articles (06/2008 - 05/2007)|
|2.||Or, Yat Sun: 2 articles (08/2009 - 05/2009)|
|3.||Jiang, Li-Juan: 2 articles (08/2009 - 05/2009)|
|4.||Motamedi, Nima: 2 articles (06/2008 - 05/2007)|
|5.||Phan, Ly Tam: 2 articles (06/2008 - 05/2007)|
|6.||Kolonoski, Peter: 2 articles (06/2008 - 05/2007)|
|7.||Bermudez, Luiz E: 2 articles (06/2008 - 05/2007)|
|8.||Wang, Michelle: 1 article (05/2009)|
|9.||Chee, Chris: 1 article (06/2008)|
|10.||Baimukanova, Gail: 1 article (06/2008)|
|1.||Pneumococcal Meningitis (Streptococcus pneumoniae Meningitis)
|3.||Body Weight (Weight, Body)
05/01/2007 - "Mice infected with macrolide-susceptible MAC strain 101 were given 100 mg of EDP-420/kg of body weight daily for 4 weeks and showed a significant reduction in the number of bacteria in both liver and spleen which was greater than the reduction observed with clarithromycin treatment at the same dose (P < 0.05). "
|4.||Respiratory Tract Infections (Respiratory Tract Infection)
05/01/2009 - "Based on its human pharmacokinetic profiles, taken together with its in vitro/in vivo activity against common respiratory pathogens, EDP-420 warrants efficacy trials for the treatment of respiratory tract infections."
08/01/2009 - "EDP-420 (also known as EP-013420, or S-013420) is a first-in-class bridged bicyclolide currently in clinical development for the treatment of respiratory tract infections (RTI) and has previously shown favorable pharmacokinetic (PK) and safety profiles after the administration of single oral doses of a suspension to healthy volunteers. "
05/01/2009 - "EDP-420 (EP-013420, S-013420) is a first-in-class bicyclolide (bridged bicyclic macrolide) currently in clinical development for the treatment of respiratory tract infections. "
03/01/2008 - "Effects of EDP-420 on penicillin-resistant and quinolone- and penicillin-resistant pneumococci in the rabbit meningitis model."
03/01/2008 - "In experimental meningitis, EDP-420 produced a bactericidal activity comparable to the standard regimen based on a combination of vancomycin with ceftriaxone against a penicillin-resistant Streptococcus pneumoniae and a penicillin- and quinolone-resistant S. "